The GNRH1 Knockout Ca Ski Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population with disrupted GNRH1 gene in the human Ca Ski cervical carcinoma line. This loss-of-function model eliminates gonadotropin-releasing hormone expression, enabling study of GnRH signaling in cancer. The polyclonal format provides a heterogeneous pool of edited cells for robust functional assays.
Ca Ski cells are an adherent epithelial line from a metastatic cervical carcinoma, containing integrated HPV16 DNA. They express wild-type p53 and Rb, functionally inactivated by viral E6/E7 oncoproteins, making them a standard model for HPV-driven cervical carcinogenesis and evaluation of anti-cancer agents.
GNRH1 encodes the hypothalamic decapeptide that binds GNRHR on pituitary gonadotropes, activating Gq/11 proteins and phospholipase C??. This triggers calcium mobilization and protein kinase C activation, leading to MAPK (ERK1/2, JNK, p38) signaling and synthesis of LH (LHB), FSH (FSHB), and their alpha subunit (CGA). Processing involves prohormone convertases (PCSK1, PCSK2) and CPE. Upstream regulators include kisspeptin (KISS1), neurokinin B (TAC3), dynorphin (PDYN), and steroids. In cancers, local GnRH may act through the same Gq/11-PLC-PKC-MAPK axis to influence proliferation and invasion.
Disrupting GNRH1 in Ca Ski cells removes autocrine/paracrine GnRH-GNRHR loops, allowing dissection of direct tumor cell effects independent of pituitary gonadotropins. This is relevant for testing GnRH analogs as potential anti-cancer agents in HPV-positive cervical cases. The model helps explore whether GnRH signaling interacts with HPV oncoprotein-driven pathways, and the polyclonal pool minimizes clonal bias.
Applications include studying GnRH signaling in cervical cancer, evaluating local GnRH in HPV carcinogenesis, and assessing GnRH analogs?? direct anti-proliferative actions. Assays such as Western blot, RT-qPCR, viability (MTT), apoptosis (Annexin V), Transwell migration, reporter assays, and RNA-seq can be employed. For protocols or inquiries, contact Ascent Research.
